Adam Feuerstein ✡️· @adamfeuerstein · X·· 8 天前精选AI 评分58
AI 导读
Zura Bio宣布,其II期TibuSHIELD研究评估tibulizumab(ZB-106)用于成人中重度化脓性汗腺炎(HS),未达到主要终点。
推荐理由
Zura Bio的II期TibuSHIELD研究未达主要终点,读者可据此了解tibulizumab在中重度化脓性汗腺炎上的开发受挫。
正文
Zura Bio $ZURA announced that its Phase 2 TibuSHIELD study, which evaluated tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS), did not meet its primary endpoint
来源:Adam Feuerstein ✡️ · x.com